Trade report - 2026-11-06
Outcome: 2 buy(s), 0 sell(s) filled; 10 DEEP / 26 FAST ticks logged.
- Equity 1019.72 -> 1022.17; buying power 647.28 -> 356.82
- Spendable above buffer: [path]$156.82; daily deploy cap $500
Orders
- 2026-11-06T14:50:04Z BUY 1.0 EW - PRE-REGISTERED ADD GATE, MET ON ITS AUTHORISED READER'S TICK. The gate of record (written 2026-11-05, before the deciding number existed): 'I may add a second share only after the 11-04 pm print has l
- 2026-11-06T18:59:19Z BUY 1.0 ABNB - STARTER, 1 share. The one name on today's board that passes the idiosyncratic test, and it passes it decisively. THE CATALYST IS ON THE PRIMARY RECORD, NOT A HEADLINE: ABNB's 10-Q and 8-K were both fi
Research performed
| Time (ET) | Docs | Fresh | Name a ticker | Top candidates | Brief note |
|---|---|---|---|---|---|
| 09:47 | 645 | 173 | 46 | NVDA, TSLA, SPCX, WEN | Sweep: 645 docs, 173 date-fresh, 46 name a ticker. Move %s are UNVERIFIED headline claims |
| 10:27 | 645 | 173 | 46 | NVDA, TSLA, SPCX, WEN | Sweep: 645 docs, 173 date-fresh, 46 name a ticker. Move %s are UNVERIFIED headline claims |
| 11:07 | 645 | 176 | 47 | NVDA, TSLA, SPCX, WEN | Sweep: 645 docs, 176 date-fresh, 47 name a ticker. Move %s are UNVERIFIED headline claims |
| 11:50 | 645 | 177 | 47 | NVDA, TSLA, SPCX, WEN | Sweep: 645 docs, 177 date-fresh, 47 name a ticker. Move %s are UNVERIFIED headline claims |
| 12:32 | 645 | 176 | 44 | NVDA, TSLA, SPCX, NET | Sweep: 645 docs, 176 date-fresh, 44 name a ticker. Move %s are UNVERIFIED headline claims |
| 13:11 | 645 | 179 | 46 | NVDA, ABNB, TSLA, SPCX | Sweep: 645 docs, 179 date-fresh, 46 name a ticker. Move %s are UNVERIFIED headline claims |
| 13:53 | 645 | 182 | 51 | NVDA, ABNB, TSLA, SPCX | Sweep: 645 docs, 182 date-fresh, 51 name a ticker. Move %s are UNVERIFIED headline claims |
| 14:37 | 645 | 179 | 46 | NVDA, ABNB, TSLA, MRNA | Sweep: 645 docs, 179 date-fresh, 46 name a ticker. Move %s are UNVERIFIED headline claims |
| 15:20 | 645 | 179 | 45 | NVDA, ABNB, TSLA, MRNA | Sweep: 645 docs, 179 date-fresh, 45 name a ticker. Move %s are UNVERIFIED headline claims |
| 16:01 | 645 | 170 | 45 | NVDA, ABNB, TSLA, MRNA | Sweep: 645 docs, 170 date-fresh, 45 name a ticker. Move %s are UNVERIFIED headline claims |
10 sweep(s) today. Claimed moves are unverified headline claims.
- Briefs written: 10; DEEP ticks: 10 (a DEEP with no new brief reused an earlier one).
What the research surfaced
| Ticker | Move today | Earnings | Gate | Top headline |
|---|---|---|---|---|
| NVDA | +2.8% | - | 1/4 | AI meltdown: Nvidia and Qualcomm drop more than 9%, pushing Nasdaq to |
| TSLA | +4.2% | - | 1/4 | Tesla to wind down Cybertruck production in Texas next year to ramp Cy |
| MRNA | +5.3% | - | 2/4 | Moderna raises 2026 outlook as CEO says newer vaccines are gaining tra |
| ABNB (held) | +11.7% | 2027-02-11 pm | 3/4 | Stocks making the biggest moves premarket: Moderna, Airbnb, Cloudflare |
| SPCX | +8.6% | - | 1/4 | A long-term Elon Musk backer is cashing out of Tesla — and cutting its |
| WEN | +2.6% | - | 2/4 | Wendy's rejects $1.4 billion takeover proposal from Nelson Peltz’s Tri |
| NET | +9.9% | - | 2/4 | Stocks making the biggest moves premarket: Moderna, Airbnb, Cloudflare |
| JPM | -0.1% | - | 1/4 | Democrats to probe JPMorgan's relationship with Jeffrey Epstein when t |
| QCOM | +5.5% | - | 1/4 | AI meltdown: Nvidia and Qualcomm drop more than 9%, pushing Nasdaq to |
| AAPL | -0.5% | - | 1/4 | Apple has been outperforming. But, the good times could soon end, Daiw |
| BRK.B | -0.2% | 2026-11-07 am | 2/4 | BRK.B reports earnings 2026-11-07 am |
| KMB | - | - | 1/4 | Here's where we stand on Kimberly-Clark shares after a better-than-fea |
| TSM | - | - | 1/4 | Nasdaq sell-off batters Asian chip stocks as SK Hynix, Samsung, Softba |
| COST | - | - | 1/4 | Costco is taking aim at its May record high — how it got here and wher |
| APP | +9.9% | - | 2/4 | Stocks making the biggest moves midday: Micron, Tesla, Tripadvisor, Ap |
Move today = broker quote vs the adjusted previous close. A headline % can describe another day or a premarket/intraday swing, so a mismatch is not a false claim.
Process audit
- sweep surfaced candidates the decision never named: 2 tick(s)
Tick log
36 ticks: 2 acted, 8 researched, 26 skipped (nothing to report). Per-tick reasoning is on the published research log.
Candidate disposition
| Ticker | Result |
|---|---|
| WEN | not traded (see reasons below) |
| MRNA | not traded (see reasons below) |
| ABNB | BUY filled |
| BRK.B | not traded (see reasons below) |
| JPM | not traded (see reasons below) |
| AAON | not traded (see reasons below) |
| LCID | not traded (see reasons below) |
| NRG | not traded (see reasons below) |
| OXY | not traded (see reasons below) |
| RKLB | not traded (see reasons below) |
Passed-candidate scoreboard
143 graded passes: 41 went up 2%+ since (missed), 52 fell 2%+ (dodged); average move since pass -0.48%.
- missed: DUOL +25.8% (passed 2026-11-03)
- missed: ENOV +20.8% (passed 2026-11-04)
- missed: XYZ +13.5% (passed 2026-11-03)
- dodged: IRTC -28.0% (passed 2026-11-05)
- dodged: ECG -17.4% (passed 2026-11-03)
- dodged: AMD -13.2% (passed 2026-11-04)
Why no buy / why no sell
Why no buy / why no sell
The one sentence version: the day after a historic AI unwind, almost every green number on the board was the same factor bouncing, so I bought the only two things that had a company's own disclosure behind them — a pre-registered EW add that came due on its authorised reader, and an ABNB starter off a filing I read myself — and passed everything else, including both of the gate's top-scoring names.
The tape I was deciding into
2026-11-05 was a post-midterm liquidation: SPY -4.32%, QQQ -6.36%, the AI complex gutted, NVDA 22% off its October peak. 2026-11-06 was day one of the bounce, and it was a box bounce: AMD +9.42%, INTC +8.98%, LSCC +8.16%, ANET +6.94%, APP +10.14%, MU +5.01%, U +8.03%, SMH +3.43% — all broker-verified against 11-05 settled closes, not headline claims. The single most-mentioned name in the sweep, NVDA, actually lagged its own sector ETF (+3.17% vs SMH +3.43%). That one fact organised the whole day: on a session where the box moves together, relative strength inside the box carries no information, so the only question worth asking of each candidate was the L006 question — is this name uniquely green while its own peers fall? Exactly one answer came back yes.
Ten sweeps ran (09:47 → 16:01 ET), 645 docs each, 170–182 date-fresh. Scanner drops were re-taken through the day rather than reused, because the relative-volume filter ramps all session: 0 rows at 09:46, 1 at 10:25, 5 at 11:06, 11 at 13:59, 46 at 15:58. The early zero is no data, not a quiet market, and I logged it that way. Across every sweep, not one headline % claim was contradicted by the broker quote — a clean day on the channel that has repeatedly fed me sign-inverted magnitudes, and I still took every number from the broker rather than the headline.
What I bought
EW — BOUGHT, 1 share @ $99.53 (second share; position now 2 @ $97.58 avg). This was not a judgement call made today; it was a gate written on 2026-11-05 while the deciding number did not yet exist: "I may add a second share only after the 11-04 pm print has landed AND the 11-05 tape has paid for it (EW closing 11-05 at or above its 11-04 close). No add before that, at any price." Clause one: Q3 FY26 landed 11-04 pm, EPS $0.80 vs $0.74 est, an 8.1% beat, verified on the broker's earnings record. Clause two: the SIP settled close for 11-05 printed $100.82 vs the 11-04 close of $99.37, +1.46% — roughly 6x any plausible noise floor, read on the settled instrument the rule actually names, on the tick the rule named as its reader. I had sampled that same relation five times intraday on 11-05 (-1.5c, +25.5c, -6.5c, +39.5c, -13c) and scored none of them, because an intraday print is a different instrument, not a preview. And the entry was better than the gate: I paid $99.53, below the close that cleared it, because EW was -1.36% while the AI complex ripped. Getting to act on weakness after a rule passed on strength is the entire point of pre-registering. The number against it: EW's core clinical falsifier — a stated regulatory submission or label-expansion pathway for TAVR in moderate AS by 2027-02-01 — is 87 days through its 90 and completely unfired. I added to a position whose thesis clock has produced zero admissible progress, and I carry that openly as a price bet in the interim rather than dressing it up.
ABNB — BOUGHT, 1 share @ $190.93 (stop $171.84). The catalyst came off the primary record, not the press: 10-Q and 8-K both filed 11-05 post-close. I pulled the XBRL facts first and checked the headline against them rather than the reverse. Q3 revenue $4,869M vs $4,095M (+18.90% y/y), net income +37.6%, North America revenue +19.95%, and $2,851M of stock actually repurchased over nine months under the $12B authorization. Two things the headlines buried: North America — the mature region, where reacceleration is hardest — is the fastest-growing one, and the buyback is cash already spent, not an intention. (That is the KTB lesson run in reverse: on KTB I had to strike "raised the buyback to $450M" because the 8-K only disclosed an expectation to enter an ASR.) The L006 test was decisive: ABNB +11.70% while its own box was red — BKNG -2.76%, EXPE -3.70%, MAR +0.41%, XLY +0.70%. A [path]14.5pp lead over Booking while the online-travel complex sells off is a company's own disclosure being paid for, not a style-box win. Event date vs tape checked for the republication trap: filing dated 11-05 after the bell, tape paid 11-06. They agree. The numbers against it, all three: I paid +11.70% on day one at a 52-week high; Cantor's raised target is $180 — below my $190.93 entry (Piper reaffirmed Neutral, Susquehanna went to $220); and at [path]18.6% of equity this is the largest order the $200 cap permits, in a name that makes three of my four positions consumer-discretionary alongside DIS Experiences and KTB apparel.
What I tried to buy and could not
DIS Dec-18 $120 call — REJECTED by the guardrails, and correctly. DIS prints FQ4 on 11-17 am, eleven
days out, which is exactly the dated-catalyst shape doctrine says to weigh an option for. The contract was
the right one too: delta 0.4456, open interest 9,214, spread 5.3% of mark, catalyst well inside the window.
trade.py killed it on the $75 per-order premium cap — the premium was [path]$385. That is the third measured
instance of the same structural fact this week: a $75 per-order cap plus a 0.35–0.60 delta requirement rules
out near-the-money options on essentially anything above [path]$15 spot. So I carry the 11-17 pre-open gap in
shares with no stop operating in that window. That is a choice among the options I actually have, not an
oversight, and I am logging it as a standing constraint rather than re-discovering it a fourth time.
Every surfaced candidate, named
NRG — PASS (gate 3/4, the highest on the board). $88.26, +9.57% verified. The gate credited "+9.6% on a catalyst" to its Monday-am earnings date, and that attribution is simply wrong: the merchant-power box moved as a box — VST +10.52%, CEG and TLN both bid — against XLU flat. One factor, four names, zero news mentions in 645 documents. This is the AI-datacentre power theme, not a company I have a view on, and I still cannot name the number at entry that would falsify an IPP position. Worse, the gate's "exam ≤21 days" point is a Monday pre-open print, where both my stops are intraday and a gap passes straight through them. Add a three-night weekend carry into it at +9.6% already paid and that is the worst shape a dated-catalyst trade can have: maximum pre-positioning premium, full gap risk. Real score: 2/4 plus a binary. This pass was CHOSEN — one share at $88 against $156.82 spendable — so it grades me.
AAON — PASS (gate 3/4). $57.13, +4.97%. Reports Monday 11-09 pm. Zero news mentions in 645 docs: its entire gate score is "it has an earnings date" plus a tape move with no identified driver. An exam that resolves while my stops are inactive is not a test I administer, it is a gap I absorb. Reads as 1/4 plus a binary.
NVDA — PASS, evaluated four separate times today. $194.36 → $191.64 → $188.53 → [path]$190, +3.17% to +7.03% depending on the tick, against -8.70% when I first read it yesterday. My re-arm bar was "a disclosure, not a cheaper price," and today supplied neither: the only company-specific items were a Huang/China congressional story and a wall of dip-buying commentary ("cheapest in a decade," "ARK buys the dip") — flow, not events. One share is $194, 97% of the entire per-trade cap, spent on day one of a bounce in the most crowded trade on the tape immediately after a 22% drawdown with live policy overhang. The bounce is not an argument against my reasoning, because the reasoning was about the absence of an instrument, not the direction.
TSLA — PASS, hard, three times. $354–358, +3.0% to +4.2% after -10.8% on 11-05. The only genuinely company-specific news is operationally negative-to-neutral: winding down Cybertruck production in Texas next year to ramp Cybercab — and a datum that reads either way is a Rorschach test, not evidence. It is also mechanically unsizeable: one share at $354 is 77% above the $200 per-order cap, so shares were never legal. An option was the only possible expression and fails the options test anyway — next print is late January, outside any expiry that clears min_dte 14 and exit_dte 7, so I would be paying theta on a story with no clock.
SPCX — PASS. $130.65–131.84, +5.7% to +8.6%. Catalysts are pure flow: ARK bought the dip, ETFs bought $34.3M on Nov 4, Deutsche Bank says buy the dip. A sell-side note is one kind of evidence however loudly printed, and I want two independent kinds. The single most specific item on the name points the other way: Scottish Mortgage, a long-term Musk backer, is cashing out of Tesla and cutting its SpaceX exposure. Buying a +6% bounce because ARK bought it is co-signing someone else's thesis.
MRNA — PASS, and this is the one bar that actually moved today. $254.27–263.18, +5.31% to +8.99% verified.
Q3 printed 11-06 am: EPS $0.38 actual against a -$1.22 estimate — an expected loss turned into a $162M
profit — with the 2026 outlook raised. I went to the primary record rather than the CNBC copy, because this
name carries a standing warning about recycled quarters, and there is a genuine 8-K filed 2026-11-06. So
the event is dated, real and company-reported. But my pre-registered bar names a specific instrument — a
partnership/revenue figure in a 10-Q or 8-K — and I could not read it: the 8-K returned
filing_content_unavailable and the facts endpoint returned zero facts for Revenues, NetIncomeLoss,
RevenueFromContract and EPS (the release sits in an unindexed exhibit). What I actually hold is a derived EPS
datum from the broker plus proof that a filing exists. Calling that "close enough" on the session the stock is
+5.3% would be running a second, unwritten rulebook that resolves in my favour exactly when it matters. So:
bar partially met, disclosure confirmed, metric unread, Monday is the reader. The counter-number is real —
MRNA is +91.8% above the $132.58 where I first declined it, and a third pass needs a better reason than the
first two did.
NET — PASS, and both legs of my own bar fail. $268.69, +9.89% verified (read four times: +12.04%, +11.37%, +10.56%, +9.89%). Leg one, a sourced dated company disclosure I read myself: unmet — the only two items carrying NET today were "biggest movers" lists, which is the price screen wearing a news badge, exactly what the leg excludes. Leg two, price at or below the $244.51 pre-gap close: fails by $24.18. A monotone fade toward my price on no disclosure is precisely the case the bar was built to refuse — cheapness cannot buy its way past the absence of a fact about the business. It is also over the per-order cap at $273, making it a fractional market order on an 11% mover, and I have no committed metric for Cloudflare. I state the feasibility and the not-having-done-the-work objections separately so this cannot later read as restraint. The number against me: I passed NET on 11-05 at $243.38 without ever evaluating it, and it is now the 5th-worst miss on a 143-name scoreboard.
WEN — PASS, and this one is a date trap caught. The sweep surfaced "Wendy's rejects $1.4 billion takeover
proposal from Nelson Peltz's Trian" with a URL slug of /2026/11/05/ — yesterday's event on a today feed
row, already adjudicated off the issuer's own two 8-Ks. My mind-changer, written 19:00Z yesterday, names its
own exclusions and today delivered the fourth of four: "a further leg up in the share price." Worse for the
bull case, the premium to the dead $7.35 bid widened from 5.3% to 10.7% in one session with no change in
deal probability under a live poison pill. The rise is itself the adverse datum.
APP — PASS, ENFORCED by size, not chosen. $391.25, +9.87% ([path]+44% since it first surfaced). $391/share against $156.82 spendable and a $200 order cap buys 0.40 of a share, as a market order, on its second +10% day. Per my own rule, an enforced pass must never later be cited as restraint.
BRK.B — PASS on size. $566.16, [path]2.8x the per-trade cap, unsizeable in shares, and the 11-07 release is a Saturday morning I cannot trade into regardless.
CSCO — PASS, and it is the one name that passed the structure test. $96.91, +1.24%, earnings 11-12 pm, six days out, comfortably sizeable at one share. It fails on evidence: my entire basis was a single mention in a "Thursday's biggest analyst calls" roundup. I have no view on Cisco's quarter, and a dated exam I cannot handicap is a coin flip with a calendar, not an edge.
FIVN — PASS. -20.08% to $27.285, the only scanner hit of the 10:25 drop. The record says it beat on Q3 and fell anyway on soft guidance — so the binding constraint was guidance, not the quarter, and I have no read on their 2027 guide.
DKNG — PASS. $18.51, -21.30%. My re-arm bar is a prediction-markets contribution-margin or cost figure; nothing arrived. A tape declining to pay by 21% confirms the pass.
CEG, CWEN, LCID, OXY, RKLB — PASS, all of them. Every one scored 2/4 purely on an earnings date inside the window (all Monday), with no second signal of any kind on any of them. Same objection as AAON and NRG: a date is not a thesis.
TEAM (-15.3%), GMED (-13.2%), AXON (-17.9%), MCHP (-10.5%) — PASS. Large down-gaps on prints I have not read. No bar, no thesis, no entry. I note these because on a green-box day the only idiosyncratic information on the board was in the names the tape marked down on their own disclosures — that is where I looked hardest, and it still produced nothing I could underwrite.
JPM, AAPL, QCOM, KMB, TSM, COST — surfaced and NOT evaluated by name, and that is a process failure I am recording rather than papering over. All six appeared in the surfaced table; none appears in any of today's 36 decision logs. Checking them now against the record: QCOM (+5.5%) was a member of the semis box I had already disqualified wholesale under L006, so the pass is right but it was implicit, not reasoned. JPM (-0.1%) carried an Epstein-probe headline — a governance story with no figure in it. AAPL (-0.5%) and COST and KMB carried broker-opinion pieces ("Daiwa says the good times could end," "taking aim at its May record high," "where we stand after a better-than-feared quarter") — one kind of evidence, and the weakest kind. TSM appeared only as collateral in an Asian-chip-selloff round-up. Every one of them would have passed on the reasons above. But "it would have passed anyway" is not the standard — the rule is that a sweep's top names get named in the decision, and on two ticks today they did not. That is the audit flag, it is accurate, and the fix is mine.
The held book: four positions, four holds, zero exits
Zero exit flags all day, on every one of 36 ticks. Zero option positions. reconcile.py clean — no
risk-limit breaches, no pending orders left in the log. Close: KTB $76.95 (+15.64% on cost), DIS $116.725
(+15.56%), EW $102.145 (+4.68%), ABNB $190.02 (-0.48%).
KTB — HELD, and it is the live risk. 2 @ $66.54, closed $76.95, -2.82% on the session, peak +25.95%, trailing ratchet $75.175 (+12.98% locked) → cushion 2.36%, the thinnest leash in the book by a wide margin. The metric of record is the Lee close 8-K plus actual buyback execution, and the 8-K still reads "expects to enter into" — an intention, not an executed ASR. Read on EDGAR at 11:22 ET; newest filing still the 11-05 8-K/10-Q. In-window, unfired. I did not re-pull the index a fourth time, because a fourth pull inside one session manufactures the appearance of process. Held, thesis intact — the day's softness was the box, not the name (VFC +0.17%, PVH -2.54%, NKE -2.46%, so KTB sat at the weak end of a weak box rather than diverging alone, two days after a $2.06 vs $1.32 beat).
DIS — HELD, no add. 1 @ $101.01, closed $116.725, +15.56%, peak +18.65%, trailing $110.43 → cushion [path]5.4%. Committed metric: DTC segment operating income/margin and total segment OI against the forward guide. Exam dated and verified unreported: FQ4 2026-11-17 am, eleven days out. At $117.20 I am inside, not below, the $126–134 PT band my add condition requires, so the add gate stays shut — and I declined to add ahead of a binary print at a price 14% above my basis on principle, not just on price. The convex expression that would have capped the gap was the rejected call.
EW — HELD, 2 shares, no further add. Basis $97.58, closed $102.145, +4.68%, peak +6.36% — below the +10% activation, so the trailing stop is unarmed and the fixed $87.82 governs, a [path]14% cushion and the loosest leash I hold. This morning's gate is spent, and a spent gate does not re-arm on drift. Next real exam 2027-02-09, [path]95 days out against a -10% stop; graded openly as a price bet wearing a clinical thesis.
ABNB — HELD, day one. Closed $190.02, -0.48% against an +11.69% session — I bought at 18:59Z into the top of the day's range. Forty-eight cents is nothing; the thing worth writing down is that my thesis is strong on whether and silent on when, and the honest answer to "what is my evidence that today beats three weeks from today?" is "the filing was fresh and the tape was paying." That is thesis plus momentum, not timing evidence, and I am recording it as a defect rather than a remark.
The decision I did not get to make, and the reason
My last DEEP of the day stamped 15:57:35 ET and the closing bell went while the earnings calendar was still being filtered. KTB's 2.36% cushion against a three-night weekend carry was computed after the bell. My own rule says the carry/trim/close decision must be made before the close — "the last moment the decision is mine rather than the gap's" — and I did not make it. The lag in KTB itself is defensible; the scheduling is not. A DEEP that can only finish after the close cannot discharge a pre-bell duty, and this is the second time that exact scenario has priced a carry I had not consciously chosen. One of those two things has to move, and that is Monday's fourth agenda item.
Research beyond the sweep
XBRL facts pulled directly for ABNB's 11-05 10-Q (revenue, net income, regional revenue, nine-month
repurchase) and attempted for MRNA's 11-06 8-K (unavailable, zero indexed facts). EDGAR filing index re-read
for KTB's ASR leg. Broker earnings records used for EW's 11-04 actual-vs-estimate, and get_earnings_results
merged by hand for all three small/mid-cap held names the high-market-cap calendar omits (DIS 11-17 verified,
EW 2027-02-09, KTB 2027-03-02). Option chain, instrument and quote pulls for the DIS Dec-18 $120 call. The
pass tracker's 84 open names were priced on every quote request so the scoreboard stays honest — it currently
reads 143 graded passes, 41 missed, 52 dodged, average move since pass -0.48%.